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Agriculture  and  food  processing,  forestry,  health  care,  pharmaceuticals 
and  major  sectors of  the  chemical  industry  are  among  the  areas  of  activity 
which  may  be  radically altered by  the  recent  breakthroughs  in biological 
science,  and  their  technological  applications.  Biotechnology  is of  fund-
amental  importance  to  every  society,  and  to  many  businesses.  In  the  United 
States,  over  200  new  companies  have  been  created,  and  several  billion dollars 
invested  in  biotechnology,  over  the  past  10  years;  giant  multinationals  are 
reorientinq  their  strategies  towards  the applied  Life  sciences,  and  spending 
massively  on  research.  In  Japan,  the exependiture  is more  modest,  but  the 
coordinating  role  of  MITI's  "Bio-industry Office"  brings  together all  the 
major  groups  in  a  concerted assault  on  the  commanding  heights  of  this, 
the other  "microtechnology".  The  dynamo  of  change  is the  breathtaking  pace 
of  scientific progress,  and  Europe  is  strong  in all  the  key  areas  - mole-
cular  and  cellular  biology,  microbiology,  process  engineering  and  fermenta-
tion  science.  But  will  the  Old  World,  with  its fragmented  markets  and  com-
plex  political  machinery,  manage  to  hold  its place  in  the  race  to  commercial-
ization? 
The  European  Community  cannot  be  passive,  faced  with  the  massive  challenge 
of  the  new  opportunities,  and  the  sharp  competitive  threat  from  the other 
industrialised  countries.  The  means  exist  within  the  Community  - the  human 
skills, the  financial  resources,  the potential  scale of  the  home  market. 
These  need  mobilisation  by  a  concerted effort,  involving  decision-makers 
both  in private  industry  and  the  public  sector;  in  small  and  Large  firms; 
at  national  Ministries,  and  in  the  Community  institutions~ 
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The  studies  and  the experience are available,  on  which  to build  a  Community 
effort.  The  Commissio~ has  argued  since  the  mid-70s  for  a  collaborative 
R and  D programme  in  the  key  areas  of  genetic  engineering and  enzymology. 
The  futures  group  FAST  (forecasting  and  Assessment  in  Science  and  Technology) 
argued  for  a  comprehensive  Community  strategy  for  biotechnology  - of  what 
use  the  advanced  research,  if  firms  are  being  driven  out  of  the  Community 
because  of  the  price of  agricultural  raw  materials?  Meanwhile,  the  develop-
ment  of  biotechnology  in  the  countries of  Europe  proceeds  slowly  and 
sporadically;  constrained by  history to gradual  innovation  and  institutional 
change,  condemned  by  future  competition  if it fails  to move  quickly  enough. 
Biotechnology  is a  "knowledge-based business",  and  therefore  R and  D 
capability  is  central.  That  capability  has  to achieve  "critical mass",  by 
developing  centres  in  Europe  with  the  equipment,  the  people  (above  all the 
broad  interdisciplinary  teams>,  the  intellectual  stimulus  and  density  in 
"brains  per  square  metre".  The  best  young  researchers  in  each  area  must  be 
able  to  find  and  move  to  centres of  world  class  within  the  Community.  By 
all means,  with  transatlantic  collaboration and  exchange  - but  a  two-way 
shuttle,  not  a  one-way  brain-drain. 
To  stimulate  the development  of  these  advanced  technologies,  at  a  pre-
competitive  level  under-pinning applications  capability,  the  Community  first 
launched  a  programme  oriented towards  the transfer of  the scientific  break-
throughs  into  European  agriculture: 
a  Multi-annual  (1982-86),  15  11illion  ECU,  cost-sharing  Research  and  Training 
Programme 
This  programme,  started  in  April  1982,  now  tncludes  104  research  contracts, 
covering  periods  between  24  and  ~0 months,  and  i!lv_?lving  Commissiqn:  co-finance 
averaging  40  000  ECU  per  year  per  laboratory.  The  six  areas,  all oriented 
to agriculture  and  the  food  industry,  comprise: 
- development  of  advanced  bior-eactors  for  agriculture and  the  food  industry; 
- improved  production of materials  for  stock  breeding  and  for  agriculture 
and  the  food  industry  through  application of  biomolecular  engineering 
techniques; 
- improvement  of  plant  products; 
- development  of  methods  for  the  identification and  transfer of  new  genetic 
information  in plants; 
-improvement  of  the  symbiotic  relations  between  cultivated plants  and  soil 
micro-organisms; 
- development  of  methods  for  cell  selection and  regeneration  in other plants. 
Wider  in  its scope,  the  training programme  covers  all  aspects  of  biomolecular 
engineering,  including  methods  of  risk  assessment  in  biotechnology. 
The  need  for  a  wider  concept  of  strategy  is  reflected  in  the  Commission's 
new  proposals  for  a  five-year,  Biotechnology  Action  Programme  (1985-89),  of 
which  Research  forms  only  the  first  of  six  points: 
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1.  Research  and  Training  - prolonging  the activities of  the  outstandingl: 
successful  first  R  and  D programme,  and  enlarging its scope  to  a  broa1  ·r 
range  of  topics  in basi.c  biotechnology;  ranging  froM  such  frontiers  a! 
"protein engineering•,  to  work  on  the  development  of better health 
diagnostic  tools,  and  better  ~thods of  toxicological  testing for  new 
drugs.  A •contextual  Me~sures• sub-programme  aims  to strengthen  the 
research  infrastructure for  biotechnology,  in data  banks,  inforMation 
services,  and banks  of genetic  Materials  (cells, lllicroorganisMs,  etc.J 
2.  Concertation  Action - for MOnitoring,  coordination,  and  the essential 
COfltftKJ.nication  functions,  betwteA  Cot~Mission services, between  biotech-
nology  policy  ~akers at  Co-.unity and  national  levels,  between  the 
various  scientific disciplines  and  econoMic  sectors.  through  inforMal 
networks  spanning  the  internal national  fronti~rs of  the  COMMUnity. 
3.  Access  to  Raw  Mat•rials._ - sug-ar  1  starch or ~  sue:!'\  organic  and 
digestible  ~n~rgy source  is  f~aaent~l to all the  fer-entation 
tndustri~s o1  biotechnology;  but  it raust  be  available- at  a  colllf;)etitive 
pr}c~, if Europe's  biotec.hnology  firms  are to tf'trive.  Proposals  for  t  ,! 
nece!sary  changes  of agricultural  regiMes  nave  been  put  to  Council.  T  ~ 
d~veloPMent, through biotechnology,  of  high-add~d-value and  non-food u  ~s 
for  agricultural  materials  is of  strategic  importance  for  the  future o 
Europe's  agriculture. 
4.  Regulatory  Regimes  - the  long-standing efforts towards  the  creation of 
a true  Co"mmon  Market  acctui re  a  new  urgency  frolll  the needs  of  biotechnol  ~Y, 
wt'fich- inctude  the- need  for  a  cle~r,  responsible  and  uniform  regulatory 
environment.  In  pharmaceutical  products, foodstuffs,  feedstuffs,  chemi  als 
and  other areas,  the  need  is  the  same:  to derive  the economies  of  seal•  and 
consequent  benefits of  a  market  of  300 million  p~ple. 
5.  Protection of  Intellectual  Property  - the  law  of patents,  and  the  con-
ventions  for  the  protection of  plant varieties,  find  some  of  their basit 
concepts  brought  into question  by  the  radical  innovations  of  biotechno  ~gy. 
Thus  the existing proliferation of different  national  systems,  both  wi·  in 
the  Community  and  worldwide,  is  further  complicated by  technical  uncer1  in-
ties at  the  interface between  science  and  jurisprudence.  Industry  -
particularly within  Europe  - chafes  at  its  impediments,  and  at  the  mar 
advantageous  conditions  inthe  USA  and  Japan;  while  jurists at  national~ 
European  and  OECO  level  wrestle  with  the  slow  processes  of  legislative 
innovation  and  the modification of  international  conventions.  The 
Commission's  working  group  on  patenting  in biotechnology  is battling tc 
assert  in this  complex  domain  the  urgent  and  growing  need  for  a  Communi  y 
approach. 
6.  Demonstration  Projects  - and  other  forms  of  closer collaboration  with 
industry,  are  seen  as  essential to  the  Community's  long-term  strategy. 
Action  and  proposals  on  this plan  have  been  intensifying  through  1984, 
the  new  five-year  Research  Programme  being  timed  to start  in  early  1985 
to  run  at  roughly  15  million  ECU  per  year  to  1989. 
The  Commission's  plan  attempts  to  address  the  strategic challenge,  but  the 
resources  are  modest,  the  constraints  on  implementation,  many  and  complex • 
• I What  are  the  competito_rs  doing? 
USA 
The  USA  are  seen  by  themselves,  and  many  others,  as  leaders  in  biotechnology. 
Since  1974,  the  proliferation of  venture capital  firms  and  the  heavy  invest-
ment  in facilities  and  research  contracts,  have  created a  thriving  and  fast-
growing  industry.  Early  leaders  such  as  Genentech,  Cetus,  and  Hybritech  are 
now  capi.talised at  a  value of  several  hundred  million dollars;  and  in  spite 
of  the  ups  and  downs  of  market  values,  shareholder expectations  and  scientific 
success  or  failure,  only  a  handful  of  the  hundreds  of  new  firms  have  so  far 
failed. 
The  science  is  in  many  cases  capitalising on  the  long-term  heavy  spending  by 
the  US  federal  institutes - the National Institutes  of  Health,  the  National 
Science  Foundation,  and  the great  departments  of  state  (Defence,  Agriculture, 
Energy).  Public  sector  funding  for  biotechnology  has  been 
estimated at  around  $550  ~illion per  annum  (1982-83).  New  products~ for 
health  care,  agricultural  productivity,  and  other applications  are  currently 
under  test,  some  of  the first  products  of  genetic  engineering already  on  the 
market.  New  forms  of  agreement  between  academic  centres  and  industry  are 
being  developed,  as  the major  chemical  and  pharmaceutical  groups  buy  access 
to the  key  strategic  resource  - knowledge. 
A  l thought he  country's l,ong history of fermented f_oods~ and .. ori  nKs is usua  ~ ly cited as the 
major initial strength of the  Japanese  in biotechnology,  a  factor  of  no  less 
strategic  significance  is the  country's ability to put  together  coherent, 
long-term  sectoral  strategies, pursued  with  the  necessary persistence over 
many  years.  The  techniques  and  applications of  biotechnology  are  now  the 
subject  of  such  a  strategy,  many  firms  seeking to establish their basic 
capabilities  in  the  new  pharmaceuticals  by  adopting  as  a  target  the  production 
of  one  of  the  interferons  <a  class of  natural  molecules of  significance  in 
the  body's  defence  system  against  virus disease). 
In  1980  on  the  initiative of  the  MITI  (Ministry of  Internat~onal ,Trade  and  Industry) 
national  programmes  were  launched:  the  Biomass  Programme  covering  a  period 
of  seven  years,  in  which  22  firms  are  cooperating  in  five sectors  (manu-
facture  of  ethanol  from  cellulose; manufacture  of  ethanol  from  starch  by 
f  using  stable enzymes;  gasification of  waste  to produce  wood-cellulose 
materials;  the  breeding of plants  for  the  manufacture  of biofuels;  the 
cultivation·  of  algae  for  fuel  manufacture),  and  the  Biotechnology  Pro-
gramme  covering  a  period of  10 years,  in  which  14  firms  in  the  pharma-
ceutical,  chemical  and  food  industries  are  cooperating  in three sectors 
(bioreactors;  cell  culture;  and  recombinant  DNA). 
It5i-s·  in  the  last of  these that the  Japanese  are  conscious  o.f. _lagging  behind 
Europe  and  the  USA,  and  are  therefore particularly concerned  to  close  the 
gap. 
Both  for  scientific needs  and  to exploit  market  opportunities,  active 
collaboration  is  sought  by  Japanese  firms  with  leading  companies  elsewhere • 
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The  countries  of  the  ~ommunity have  each  developed  initiatives and  rE  ponses 
to the  problems  and  challenges  of  biotechnology. 
Germany  was  amongst  the  first  to give official  recognition  to  the  im~  rtance 
of  the  field,  when  in  1974  the  Ministry  for  Research  and  Technology  C  MFT) 
took  up  the  suggestions  of  a  DECHEMA  report  <the  German  Chemical  Equi  ment 
Manufacturers•  Association>.  This  association  has  remained  an  activE  pro-
moter  of  biotechnology,  both  in  Germany  and  at  European  level:  being 
founder  association  and  secretariat of  the  European  Federation  of  Bic  ech-
nology  (founded  in  1978,  and  now  comprising  49  scientific socie1  es, 
from  18  European  countries>.  The  German  research effort is focussed  n 
major  centres  at  Braunschweig  and  Julich,  as  well  as  at many  other  Pl  lie 
or  private  institutions,  such  as  the  Technical  University of  Berlin. 
Hoechst,  the  world  leader  in pharmaceutical  (particularly antibiotic: 
production,  has  also  pioneered production of ~tn·9-e-cell protein  for  I 
oonsumption<with  BMFT  co-finance).  Boehringer  Mannheim  is a  leader· 
new  biochemicals  - restriction enzymes  and  oligonucleotides- used  ir 
genetic  engineering •.  Boehringer  Ingelheim produces  specialty  chemic< 
fermentation  (citric acid).  Bayer,  number  two  in  pharmaceuticals  wo1 
wide,  applies  enzymology  to the  production of  semi-synthetic  penicill 
Schering  uses  microbial  transformations  in producing  steroid  hormone~ 
Degussa  produces  amino  acids  (for  animal  nutrition)  using  immobilise« 
biocatalysts.  There  are  so•e  twenty  other significantly active  compi 
although  these  are  usually established  firms .rathet than  venture-cap· 
activitie·s  on"the_  US  model. 
Of  the  European  Community  countries,  the  United  Kingdom  has  the  stro1 
research  base  in  biotechnology,  with  world  class  centres  in  many  of  · 
key  disciplines.  The  institutes of  the  Medical  Research  Council  (e.~ 
molecular  biology,  Cambridge),  and  of  the  Agricultural  and  Food  Rese, 
Council  (e.g.  the  John  Innes  Institute,  Norwich)  complement  strong 
university departments;  and  another  public  institute of  special  impo 
to biotechnology  is  the  Centre  for  Applied  Microbiology  and  Research 
Parton  Down,  strong  in  fermentation  science,  and  home  of  a  recently 
founded  centre  for  animal  cell  lines. 
Industrial  biotechnology  in the  UK  is  represented  by  leading  chemica 
firms,  as  in  ICI
1s  'Pruteen'  plant  for  single~cell protein combining 
major  innovation  in engineering  (the air-lift continuous  fermenter) 
a  major  innovation  in nutrition.  In  fermentation  for  pharmaceuticals 
and  Beechams  are  well  known,  and  G.  D.  Searle and  Wellcome  are also 
for  their capability  in genetic engineering.  In  agro-food,  Unilever 
success  in  cloning  cells of the oil-palm is a  breakthrough  in applie 
genetics  of  major  practical benefit;  Ranks  Hovis  McDougall's  mycopro 
is another  promising  food  innovation. 
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The  UK  also  has  many  smaller,  venture-capital  companies,  with  specia 
skills or application areas,  or  providing ancillary services  and  sup  .ies 
to the  larger  firms.  Celltech,  launched  by  government  co-finance  wi  1 
industry,  is  strong  in  animal  cell  culture and  in  the production of  1  ,no-
clonal  antibodies  (for diagnostic  or  analytical  applications),  as  is  :o  be 
expected  in  view  of  its original  links  with  the  institutes of  the  Me·  cal 
Research  Council;  a  simi tar  link  with  the  Agricultural  institutes pr'  ,ides 
access  to  the  knowledge  base  for  Agricultural  Genetics  Co.  Ltd. 
.I. 
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France,  the  country  of  Louis  Pasteur,  seemed  to  be  falling  behind  in  bio-
technology until  a  strongly  renewed  government  interest  was  signalled  in 
1979-80  with  the publication of  strategic analyses  and  reports,  by  Gros, 
Jacob  and  Roger  <"Sciences  de  La  Vie  et  Sociiti">, de  Rosnay  C"Bio-Industrie"), 
and  subsequently Pelissolo  <"La  Biotechnologie,  Demain?">.  The  Pelissolo 
recommendations  for  the  creation of  a  "Mission  Biotechnologie"  were  accepted, 
leading  to  the  launch  of  the national  "Programme  Mobilisateur".now  being 
implemented.  This  focusses  national efforts  in  biotechnology  on  four  •poles' 
in  particular:  Toulouse,  Compiegne  (long  known  for  its enzyme  engineering 
and  bio-process  technology>,  Pasteur  Institute  Ca  private foundation, 
50%  financed  by  government,  with  capabilities  in genetic engineering, 
hybridoma  technology,  virology  and  immunology>,  and  Paris-Grignon  (the 
newly  rebuilt  centre of  fermentation  technology of  INRA,  the  National 
rnstitut-e for  Agricultural  Research).  A particular objective of  these  centres 
is to  improve  the transfer of  knowledge  into  industry.  The  strong  molecular 
biology at  the  University of  Strasbour-g  should  also be  mentioned. 
In  addition to  the  many  multi-nationals  with  strong bases  in  France,  major 
French  companies  using  biotechnology  in fine  chemicals  and  pharmaceuticals 
include  Rhone-Poulenc  <antibodies,  and  world  leader  in production of  vitamin 
812>,  with  its subsidiaries  Institut Mjrieux  (for vaccines)  and  Genetica 
(for genetic engineering>;  and  Roussel-Uclaf  <a  subsidiary of  Hoechst>  for 
antibodies  and  steroids.  But  the  Largest  commitment  to biotechnology  comes 
from  the oil  company  Elf  Aquitaine.  In  human  biologicals,  it has  acquired 
Sanofi,  Clin Midy,  Choay  and  Institut Pasteur  Production.  Elf  Bioindustries 
and  Elf  Bioresearch are developing  biotechnology  in  the  food  and  agri-
cultural  sectors.  There  are  research-minded  companies  in  the  dairy  industry 
(Bel-Industries,  BSN-Gervais-Danone,  Entremont),  and  in  starch  conversion, 
Raquette  Freres  are  world  leaders  in  sorbitol  production.  In  animal  feeds, 
amino  acids are  produced  by  Orsan,  Eurolysine  <associated  with  Ajinomoto> 
and  Rhone-Poulenc. 
Of  new  biotechnology  companies  set  up,  Genetica  has  been  mentioned;  and 
Transgene,  in genetic  engineering,  benefits  from  its proximity  to the 
university of Strasbourg. 
A report  on  "Biotechnology  in  Italy"  was  recently prepared  by  the  Federation 
of Scientific and  Technical  Associations  <FAST  - Federazione  Associazioni 
Scientifiche e  Techniche>.  The  report  lists 142  university  institutes, 
the  "Consiglio Nazionale delle Ricerche"  CCNR- National  Research  Council) 
and  public  and  private bodies  and  laboratories  of  the  ENEA  CEnte  per  l'energia 
nucleare  e  energie alternative - Association  for  Nuclear  Energy  and  Alterna-
tive  Energy  Resources>.  The  FAST  report  examines  the  key  aspects of bio-
technology,  which  in  future  will  affect  the pharmaceutical  and  chemical 
industries, agriculture,  new  construction materials and-.energy.  In  this 
connection,  a  number  of  application-oriented projects conducted  by  the  CNR 
should  be  mentioned  (fine chemicals,  biomedical  technol~ies, further 
resources  for  improving  agricultural yields). 
The  FAST  list mentions  eight  industrial  unde,.takings:  Fflmitalia-Carlo  Erba 
<Montedison  Group):  Assoreni  (this association  conduGt  .,.  ·  search activities 
for  the  companies  of  the  ENI  Group).  Lepetit,  the  Ces;·  ~.,:  Serono  Insti~ute, 
Sarin  Biomedia  (Fiat  Group>;  Spa  <a  company  for  the  mantfacture of antl-
biotics),  Recordati  and ·Solavo.  According  to the  FAST  -itudy,  Italy  has  no 
lack  either of  undertakings  or  of  research  capacities  t~t could  conduct 
key  programmes  in  the  field of  biotechnology:  where  app;J:1cability  is  concerned, 
however,  everything  waul~ have  to  be  better  coordinated~~ 
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In  addition,  mention  should  be  made  of  the  International  Centre  for  Gen  tic 
Enoineerinq  and  biote~hnolcgy set  up  on  the  initiative of  Italy under  t 
ae~is of  U~IDOr  for  which  the  Italian Government  allocated about  40  mil  ion 
doll~rs, divided  between  the first  two  scientif~c facilities,  namely  th  ;e 
at  New  Delhi,  India,  a~d at  the Trieste Research  Centre,  Italy,  which  ar 
intended  both  for  training  and  for  exchanges  wich  developing  countries. 
The  Netherlands  is outstandingly strong  in  biotechnology,  in  industria 
companies,  acad2mic  departments,  and  a  light  but  well-organised structu 
for  national  coordination4 
The  Netherlar1ds  has  an  excellent  tradition of  microbiology,  biothemistr  and 
process  engineering,  and  has  a  leading  international position  in  efflue 
treatment,  developed  in  response  to  the  needs  of  the  food  industries. 
The  company  Gist-Brocades  is  Europe's  major  producer  of  penicillin,  wit 
corresponding  expertise  in  fermentation  technology.  It  is also one  of  1e 
world's  major  producers  of  enzymes,  and  is  carrying out  intensive  study  m 
their production,  isolation and  application,  on  laboratory  and  commerci 
scale.  Related  research  is under  way  at  the universities of  Delft  and 
Wageningen.  In  the  food  industry,  Dutch  breweries  and  dairy plants  are 
sophisticated  and  internationally competitive. 
Academic  strengths  in  biotechnology  include  the  universities of  Amsterd  1 
(microbial  physiology),  Leiden  (genetics),  Groningen  (protein crystallo,  ·aphy, 
molecular  dynamics),  Wageningen  (which  along  with  the various  research 
institutes there,  covers  a  wide  range  of  agricultural  sciences)  and  Del 
(where  the  Technical  University  has  a  close association with  industrial 
fermentation). 
Biotechnology  is also  very  strong  in  Denmark,  whose  economy  is based  on 
agriculture  C24%  of  output~ food  processing  (34%)  and  chemical  industry 
C10i.).  Everyone  has  heard  of  the  Carlsberg  brewery,  with  its tradition• 
skills  in  brewing,  which  have  supported  the  creation of an  internationa 
research  centre  with  outstanding  competence  in  plant genetics  and  cell 
biology.  Everyone  has  also heard of  Novo,  which  dominates  the  world  ma1  et 
in  industrial  enzymes:  Novo  practised biotechnology  before  the  word  wa: 
invented,  and  is  now  arguably  the  world's  leading  company  in the field. 
In  1978,  the  Danish  Technical  Research  Council,  under  the  chairmanship ( 
Prof.  0.  B.  Jorgensen,  of  the  Technical  University,  took  the first  init·  tive 
in the field  and  supported  projects  in  genetic  engineering scale-up  probl  ms 
(with  particular reference  to genetic stability), product  recovery  Cwitt 
special  reference  to  selective  recovery  of  intracellular products)  and 
on  protein  synthesis.  More  recently,  a  Ministry  of  Industry "initiativE 
group"  recommended  against  creating a  new  institute specially for  biote<  -
nology  because  the  subject  was  of  such  widespread  interest  that  it needE 
to be  practised widely. 
Belgium  has  a  strong  chemical  industry,  and  outstanding strengths  in  its 
universities  and  research  institutes  in  the  biomedical  sector  (e.g.  the 
Institute for  Celtular  and  Molecular  Pathology)  and  in plant  genetics 
(University of  Ghent),  as  well  as in·othe·r  areas  <e.g.  bacteriology  in 
various  institutions).  The  international  pharmaceutical  companies  are  a  so 
attracted by  the  high  quality environment  provided by  the  research  tea~s 
in  the various  universities of  the  country. 
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At  the  level  of  the  regional  authorities,  Wallonie,  Flanders  and  Brussels 
are  seeking  to attract  foreign  investment  in  high  technology  sectors  such 
as  biotechnology;  Wallonie  and  Flanders  have  each  created  two  R and  0 
companies.  Hybritech  (the  US  leader  in  hybridoma  technology  and  marketing) 
has  established a  plant  at  Liege;  Biogen  (the  Swiss  and  US-based  group 
owned  by  Monsanto,  International  Nickel,  Schering-Plough and  Grand 
Metropolitan  Hotels)  has  established a  subsidiary at  Ghent  (Biogent).  At 
the  level  of  the national  authorities,  the  IRSIA  - a  national  industrial 
research  association  - is  coordinating  R and  D projects on  biotechnology 
topics,  and  its Biotechnology  Committee  comprises  32  companies  from  various 
industrial  sectors  and  university  laboratories  specialising  in  monoclonal 
antibodies,  fermentation,  immunology  and  genetic  engineering. 
Ireland,  like  Belgium,  is  vigorously  seeking  to attract  foreign  investment 
to  take  advantage  from  its developed  educational  system,  and  to  stimulate 
greater exploitation of  the  country's under-utilised agricultural  potential. 
The  1981  report  by  the  National  Board  for  Science  and  Technology  <NBST>, 
"Biotechnology  Trends"  emphasised  chemicals,  pharmaceuticals,  health-care 
and  food  processing  as  sectors within  which  there are  processes  and  products 
of  special  potential  significance.  The  possibility of  gaining  technology 
transfer  from  innovative  US  companies  is noted.  Innovative  companies  include 
Biocon  <enzymes),  and  several  of  the  agricultural  cooperatives  (e.g.  Kerry 
Farmers). 
In  Greece,  the  Ministry  of  Coordination,  in  consultation with  the  Ministries 
of  Science  and  Technology,  Education  and  Agriculture,  is currently  developing 
plans  to  stimulate awareness,  education  and  application of  biotechnology, 
in  the  context  of  the  1983-88  5-year plan  for economic and  social  development. 
This  includes  a  programme  for  scientific and  technological  development,  an 
element  of  which  concerns  "key  technologies", containing  three  themes: 
a)  microelectronics  and  informatics 
b)  biotechnology 
c)  technologies  relating to marine  exploitation. 
This  choice  reflects  top-level political decisions,  and  ambitious  plans  are 
now  being  implemented- to  create the necessary  foundations. 
Biotechnology  and  life sciences  research  are  being  vigourously  promoted  at 
the  new  Institute for  Molecular biology  and  Biotechnology  in Heraklion, 
Crete;  as  well  as  at  several other universities  (Athens,  Patras, 
Thessalonika)  and  at  research  centres  such  as  the  National  Hellenic  Research 
Foundation,  the  Cancer  Research  Centre  (Salonika),  and  NRC  Demokritos  (Athens). 
Professor  Stavropoulos,  associated with  the  science-based biotechnology 
company  Vioryl  (food additivies, preservatives,  flavourings,  plant  nutrients), 
is working  with  the  government  planners  to  identify  new  industrial opportuni-
ties  in  biotechnology.  there has  been  created  a  national  company, 
"Bio-Hellas",  which  will  work  in close association with  the  research  centres 
mentioned. 
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The  new  strengths of  European  biotechnology are  based  not  only  in  cour  ries 
of  the  Community.  Switzerland•s great  pharmaceutical  companies  (RochE 
Ciba-Geigy,  Sandoz)  are  active  in the  new  molecular genetics  and  immur  logy, 
and  Biogen  (Geneva-based)  is  one  of  the  leading  new  companies  in  inter  eron 
and  vaccine  synthesis,  and  the  manufacture of  diagnostic  reagents.  Tt 
Technical  High  School  at  Zurich  is a  ~entre for  fermentation  research.  In 
Scandinavia  too  there  are  Leading  centres  - the university of  Uppsala  as 
close  links  with  Sweden's  pharmaceutical  groups  <Fortia,  Pharmacia,  Kc  i-
Vitrum),  while  in  Finland  there are biotechnology  strengths  ranging  fr  m 
alcoholic  drinks  to  the  management  of  chlorinated effluents  in  the  pa~  r 
industry. 
The  role  of  the  European  Community 
The  strength  and  diversity of  European  capabilities  in  biotechnology  t  ve 
been  briefly  indicated.  These  capabilities  include all application ar  as 
in  industry,  agriculture,  health  care  and  environmental  or  resource 
management,  and  all the  relevant  areas  of  fundamental  science  and  advc  ced 
technology.  Of  no  single  European  country  could  this be  said.  Indus1  ial-
ists need  to  recover  the  heavy  R and  D costs  and  capital  investments  t 
the  economies  of  scale achieved only at  European  and  world  level.  Stuc  nts 
and  researchers  need  access  to  world-class  centres  where  the  key  resot  ces 
and  accumulated  multi-disciplinary expertise are available;  such  acce~  , 
for  collaboration,  service  and  training,  is no  less  necessary  for  tho~ 
concerned  with  applications. 
To  create  in  biotechnology  this  •espace  europeen
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initiatives are  needed  in  several  policy  areas:  in  research,  in agrict  ture, 
in  regulations,  in  industrial  policy.  These  policy  initiatives have  1  be 
based  on  a  concerted  approach,  not  only  within  the  Commission  services  but 
between  the  Community  institutions  and  national  administrations,  and  i 
association with  those  groupings or  institutionswhich~ommand the  key 
scientific,  industrial  and  agricultural strengths.  In this way,  Europe  can 
reasonably  expect  to  win  and  retain  a  position  in world  biotechnology 
commensurate  with  its high  potential. 